Biotech Values

[DewDiligence]

After MRK’s “Substance P” candidate for depression bombed a few months ago, you had a feeling MRK would try to get something else cooking in this market segment.

Today’s deal with MRK and DOVP’s prior out-license of the insomnia med, Indiplon, to NBIX give DOVP some credibility as a discovery/early development engine.